Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • Resource and Technical Advances
    • Clinical Medicine
    • Reviews
    • Editorials
    • Perspectives
    • Top read articles
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Transfers
  • Advertising
  • Job board
  • Contact
Macrophage miR-149-5p induction is a key driver and therapeutic target for BRONJ
Xin Shen, … , Rongyao Xu, Hongbing Jiang
Xin Shen, … , Rongyao Xu, Hongbing Jiang
Published August 22, 2022
Citation Information: JCI Insight. 2022;7(16):e159865. https://doi.org/10.1172/jci.insight.159865.
View: Text | PDF
Research Article Bone biology

Macrophage miR-149-5p induction is a key driver and therapeutic target for BRONJ

  • Text
  • PDF
Abstract

Bisphosphonate-related (BP-related) osteonecrosis of the jaw (BRONJ) is one of the severe side effects of administration of BPs, such as zoledronic acid (ZA), which can disrupt the patient’s quality of life. Although the direct target of skeletal vasculature and bone resorption activity by BPs has been phenomenally observed, the underlying mechanism in BRONJ remains largely elusive. Thus, it is urgently necessary to discover effective therapeutic targets based on the multifaceted underlying mechanisms in the development of BRONJ. Here, we determined the inhibitory role of ZA-treated macrophages on osteoclast differentiation and type H vessel formation during tooth extraction socket (TES) healing. Mechanistically, ZA activated the NF-κB signaling pathway and then induced p65 nuclear translocation in macrophages to promote miR-149-5p transcription, resulting in impaired osteoclast differentiation via directly binding to the Traf6 3′-UTR region. Moreover, we identified that miR-149-5p–loaded extracellular vesicles derived from ZA-treated bone marrow–derived macrophages could regulate biological functions of endothelial cells via the Rap1a/Rap1b/VEGFR2 pathway. Furthermore, local administration of chemically modified antagomiR-149-5p was proven to be therapeutically effective in BRONJ mice. In conclusion, our findings illuminate the dual effects of miR-149-5p on skeletal angiogenesis and bone remolding, suggesting it as a promising preventive and therapeutic target for BRONJ.

Authors

Xin Shen, Weiwen Zhu, Ping Zhang, Yu Fu, Jie Cheng, Laikui Liu, Rongyao Xu, Hongbing Jiang

×

Figure 6

miR-149-5p directly binds to the 3′-UTR of Traf6 and impedes osteoclast differentiation.

Options: View larger image (or click on image) Download as PowerPoint
miR-149-5p directly binds to the 3′-UTR of Traf6 and impedes osteoclast ...
(A) TRAP staining showing osteoclast formation after treatment with PBS or ZA. Scale bars: 100 μm. n = 3. (B) Wheat germ agglutinin staining showing bone resorption pits (red arrowheads) after treatment with PBS or ZA. Scale bars: 100 μm. n = 3. (C) Western blot and semiquantitative analysis of NFATc1 and CTSK expression. n = 3. (D) TRAP staining and bone resorption pits (red arrowheads) assay of osteoclasts after transfection with miR-149-5p mimics or inhibitors. Scale bars: 100 μm. n = 3. (E) Western blot and semiquantitative analysis of NFATc1, CTSK, and TRAF6 expression. n = 3. (F) WT and mutant Traf6 vectors were subjected to dual-luciferase reporter assays. n = 5. (G) TRAP staining showing osteoclast formation after treatment with ZA+NC inhibitors (ZA and miR-149-5p negative control) or ZA+ inhibitors (ZA and miR-149-5p inhibitors). Scale bars: 100 μm. n = 3. (H) Wheat germ agglutinin staining showing bone resorption pits (red arrowheads) after treatment with ZA+NC inhibitors or ZA+ inhibitors. Scale bars: 100 μm. n = 3. (I) Western blot and semiquantitative analysis of NFATc1 and CTSK expression. n = 3. Results are presented as the mean ± SD. *P < 0.05; **P < 0.01; #P > 0.05 by Student’s t test.

Copyright © 2023 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts